{"id":60243,"date":"2026-06-04T23:03:19","date_gmt":"2026-06-04T14:03:19","guid":{"rendered":"https:\/\/japanir.jp\/en\/company\/company-4591\/"},"modified":"2026-08-23T13:29:35","modified_gmt":"2026-08-23T04:29:35","slug":"company-4591","status":"publish","type":"company","link":"https:\/\/japanir.jp\/en\/company\/company-4591\/","title":{"rendered":"RIBOMIC INC"},"content":{"rendered":"","protected":false},"featured_media":0,"template":"","meta":{"Ticker":"4591","DATE":"2026-01-09","longName":"Ribomic Inc.","company_name_ja":"","fullTimeEmployees":25,"address":"","phone":"","website":"https:\/\/www.ribomic.com","industry":"Biotechnology","sector":"Healthcare","regularMarketPrice":84,"financialCurrency":"","marketCap":4333,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":-23.07,"epsForward":0,"bookValue":0,"totalRevenue":3000000,"OperatingIncome":-1207132000,"operatingMargins":-40237.730000000003,"NetIncome":-1145360000,"profitMargins":-38178.669999999998,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":-40.310000000000002,"recommendationMean":0,"recommendationKey":"none","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"{\"success\": true, \"fetched_at\": \"2026-08-01T03:49:32.672383\", \"ticker\": \"4591\", \"ticker_full\": \"4591.T\", \"company_name\": \"RIBOMIC INC\", \"analyst_recommendations\": {\"has_data\": true, \"recommendation_key\": \"none\", \"recommendation_mean\": null, \"total_analysts\": null, \"strong_buy\": null, \"buy\": null, \"hold\": null, \"sell\": null, \"strong_sell\": null}, \"target_prices\": {\"has_data\": true, \"current\": 73.0, \"high\": null, \"low\": null, \"mean\": null, \"median\": null}, \"earnings_dates\": {\"has_data\": false}, \"shareholders\": {\"has_data\": true, \"insider_pct\": 2.91, \"institution_pct\": 4.82, \"major_holders\": [{\"label\": \"\", \"value\": 2.91}, {\"label\": \"\", \"value\": 4.82}, {\"label\": \"\", \"value\": 4.97}, {\"label\": \"\", \"value\": 3.0}], \"institutional_holders\": [], \"mutualfund_holders\": []}}","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"Ribomic Inc. engages in the discovery and development of pharmaceutical compounds using RNA aptamers in Japan and Europe. The company develops RBM-007, which is in Phase III clinical trial for the treatment of achondroplasia; Phase II clinical trial for the treatment of wet age-related macular degeneration; and pre-clinical trial for the treatment of diabetic macular edema. It is also involved in the development of drugs in pre-clinical trial stage, including RBM-006 for the treatment of retinal disease, proliferative, vitreoretinopathy, glaucoma, and diabetic retinopathy; RBM-011 for the treatment of pulmonary arterial hypertension; RBM-003 for the treatment of heart failure; RBM-010 for the treatment of osteoarthritis; and RBM-009 for the treatment of severe asthma, as well as RBM-101, which is in discovery stage for the affinity purification of human IgG and Fc-fusion proteins. The company was incorporated in 2003 and is headquartered in Minato, Japan.","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"financial_data":"","detailed_financial_data":"{\"success\": true, \"fetched_at\": \"2026-08-23T01:55:24.499031\", \"ticker\": \"4591\", \"ticker_full\": \"4591.T\", \"company_name\": \"RIBOMIC INC\", \"company_info\": {\"name_en\": \"RIBOMIC INC\", \"long_name\": \"Ribomic Inc.\", \"sector\": \"Healthcare\", \"industry\": \"Biotechnology\", \"website\": \"https:\/\/www.ribomic.com\", \"employees\": 25, \"country\": \"Japan\", \"city\": \"Minato\", \"address\": \"Shirokanedai Usui Building\", \"description\": \"Ribomic Inc. engages in the discovery and development of pharmaceutical compounds using RNA aptamers in Japan and Europe. The company develops RBM-007, which is in Phase III clinical trial for the treatment of achondroplasia; Phase II clinical trial for the treatment of wet age-related macular degeneration; and pre-clinical trial for the treatment of diabetic macular edema. It is also involved in the development of drugs in pre-clinical trial stage, including RBM-006 for the treatment of retinal disease, proliferative, vitreoretinopathy, glaucoma, and diabetic retinopathy; RBM-011 for the treatment of pulmonary arterial hypertension; RBM-003 for the treatment of heart failure; RBM-010 for the treatment of osteoarthritis; and RBM-009 for the treatment of severe asthma, as well as RBM-101, which is in discovery stage for the affinity purification of human IgG and Fc-fusion proteins. The company was incorporated in 2003 and is headquartered in Minato, Japan.\"}, \"price_trend\": {\"ma_5\": {\"ma_value\": 80.8, \"deviation\": 0.25, \"trend\": \"up\"}, \"ma_25\": {\"ma_value\": 75.44, \"deviation\": 7.37, \"trend\": \"up\"}, \"ma_75\": {\"ma_value\": 71.21, \"deviation\": 13.74, \"trend\": \"up\"}, \"ma_200\": {\"ma_value\": 80.23, \"deviation\": 0.96, \"trend\": \"up\"}}, \"financials\": {\"years\": [{\"year\": 2026, \"revenue\": 3000000.0, \"revenue_fmt\": \"\u00a53.0M\", \"gross_profit\": 0, \"gross_profit_fmt\": \"N\/A\", \"operating_income\": -1207132000.0, \"operating_income_fmt\": \"-\u00a512\u5104\", \"ebit\": -1207132000.0, \"ebit_fmt\": \"-\u00a512\u5104\", \"net_income\": -1145360000.0, \"net_income_fmt\": \"-\u00a511\u5104\", \"eps\": -23.07, \"operating_margin\": -40237.73, \"total_assets\": 2976215000.0, \"total_assets_fmt\": \"\u00a530\u5104\", \"total_equity\": 2841123000.0, \"total_equity_fmt\": \"\u00a528\u5104\", \"total_debt\": 0, \"total_debt_fmt\": \"N\/A\", \"total_cash\": 1927180000.0, \"total_cash_fmt\": \"\u00a519\u5104\", \"equity_ratio\": 95.46, \"de_ratio\": 0.0, \"current_ratio\": 21.68, \"operating_cf\": -1110863000.0, \"operating_cf_fmt\": \"-\u00a511\u5104\", \"investing_cf\": 289832000.0, \"investing_cf_fmt\": \"\u00a53\u5104\", \"financing_cf\": 911054000.0, \"financing_cf_fmt\": \"\u00a59\u5104\", \"free_cf\": -1121030000.0, \"free_cf_fmt\": \"-\u00a511\u5104\", \"net_margin\": -38178.67, \"roe\": -40.31, \"roa\": -38.48}, {\"year\": 2025, \"revenue\": 2107000.0, \"revenue_fmt\": \"\u00a52.1M\", \"gross_profit\": 0, \"gross_profit_fmt\": \"N\/A\", \"operating_income\": -1050589000.0, \"operating_income_fmt\": \"-\u00a511\u5104\", \"ebit\": -1050589000.0, \"ebit_fmt\": \"-\u00a511\u5104\", \"net_income\": -1018939000.0, \"net_income_fmt\": \"-\u00a510\u5104\", \"eps\": -25.21, \"operating_margin\": -49861.84, \"total_assets\": 3185842000.0, \"total_assets_fmt\": \"\u00a532\u5104\", \"total_equity\": 3043632000.0, \"total_equity_fmt\": \"\u00a530\u5104\", \"total_debt\": 0, \"total_debt_fmt\": \"N\/A\", \"total_cash\": 1837123000.0, \"total_cash_fmt\": \"\u00a518\u5104\", \"equity_ratio\": 95.54, \"de_ratio\": 0.0, \"current_ratio\": 22.13, \"operating_cf\": -996966000.0, \"operating_cf_fmt\": \"-\u00a510\u5104\", \"investing_cf\": 67178000.0, \"investing_cf_fmt\": \"\u00a567.2M\", \"financing_cf\": 667263000.0, \"financing_cf_fmt\": \"\u00a57\u5104\", \"free_cf\": -1029787000.0, \"free_cf_fmt\": \"-\u00a510\u5104\", \"net_margin\": -48359.71, \"roe\": -33.48, \"roa\": -31.98}, {\"year\": 2024, \"revenue\": 0.0, \"revenue_fmt\": \"N\/A\", \"gross_profit\": 0, \"gross_profit_fmt\": \"N\/A\", \"operating_income\": -1116193000.0, \"operating_income_fmt\": \"-\u00a511\u5104\", \"ebit\": -1116193000.0, \"ebit_fmt\": \"-\u00a511\u5104\", \"net_income\": -1024237000.0, \"net_income_fmt\": \"-\u00a510\u5104\", \"eps\": -28.7, \"operating_margin\": 0, \"total_assets\": 3547257000.0, \"total_assets_fmt\": \"\u00a535\u5104\", \"total_equity\": 3391448000.0, \"total_equity_fmt\": \"\u00a534\u5104\", \"total_debt\": 0, \"total_debt_fmt\": \"N\/A\", \"total_cash\": 2099743000.0, \"total_cash_fmt\": \"\u00a521\u5104\", \"equity_ratio\": 95.61, \"de_ratio\": 0.0, \"current_ratio\": 22.51, \"operating_cf\": -932757000.0, \"operating_cf_fmt\": \"-\u00a59\u5104\", \"investing_cf\": 177272000.0, \"investing_cf_fmt\": \"\u00a52\u5104\", \"financing_cf\": 27649000.0, \"financing_cf_fmt\": \"\u00a527.6M\", \"free_cf\": -955484000.0, \"free_cf_fmt\": \"-\u00a510\u5104\", \"net_margin\": 0, \"roe\": -30.2, \"roa\": -28.87}, {\"year\": 2023, \"revenue\": 65969000.0, \"revenue_fmt\": \"\u00a566.0M\", \"gross_profit\": 0, \"gross_profit_fmt\": \"N\/A\", \"operating_income\": -1786041000.0, \"operating_income_fmt\": \"-\u00a518\u5104\", \"ebit\": -1786041000.0, \"ebit_fmt\": \"-\u00a518\u5104\", \"net_income\": -1653002000.0, \"net_income_fmt\": \"-\u00a517\u5104\", \"eps\": -53.14, \"operating_margin\": -2707.39, \"total_assets\": 4583655000.0, \"total_assets_fmt\": \"\u00a546\u5104\", \"total_equity\": 4384351000.0, \"total_equity_fmt\": \"\u00a544\u5104\", \"total_debt\": 0, \"total_debt_fmt\": \"N\/A\", \"total_cash\": 2825182000.0, \"total_cash_fmt\": \"\u00a528\u5104\", \"equity_ratio\": 95.65, \"de_ratio\": 0.0, \"current_ratio\": 22.79, \"operating_cf\": -1708626000.0, \"operating_cf_fmt\": \"-\u00a517\u5104\", \"investing_cf\": 276353000.0, \"investing_cf_fmt\": \"\u00a53\u5104\", \"financing_cf\": 1333771000.0, \"financing_cf_fmt\": \"\u00a513\u5104\", \"free_cf\": -1732556000.0, \"free_cf_fmt\": \"-\u00a517\u5104\", \"net_margin\": -2505.73, \"roe\": -37.7, \"roa\": -36.06}], \"has_data\": true}, \"dividends\": {\"history\": [], \"has_data\": false}}","ma_5_value":0,"ma_5_deviation":0,"ma_5_trend":"","ma_25_value":0,"ma_25_deviation":0,"ma_25_trend":"","ma_75_value":0,"ma_75_deviation":0,"ma_75_trend":"","ma_200_value":0,"ma_200_deviation":0,"ma_200_trend":"","previousClose":0,"open":0,"dayHigh":0,"dayLow":0,"volume":0,"averageVolume":0,"revenueGrowth":0},"sector":[],"class_list":["post-60243","company","type-company","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>RIBOMIC INC - Japan IR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/japanir.jp\/en\/company\/company-4591\/\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4591\/\",\"url\":\"https:\/\/japanir.jp\/en\/company\/company-4591\/\",\"name\":\"RIBOMIC INC - Japan IR\",\"isPartOf\":{\"@id\":\"https:\/\/japanir.jp\/en\/#website\"},\"datePublished\":\"2026-06-04T14:03:19+00:00\",\"dateModified\":\"2026-08-23T04:29:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4591\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/japanir.jp\/en\/company\/company-4591\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4591\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/japanir.jp\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"RIBOMIC INC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/japanir.jp\/en\/#website\",\"url\":\"https:\/\/japanir.jp\/en\/\",\"name\":\"Japan IR\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/japanir.jp\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"RIBOMIC INC - Japan IR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/japanir.jp\/en\/company\/company-4591\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/japanir.jp\/en\/company\/company-4591\/","url":"https:\/\/japanir.jp\/en\/company\/company-4591\/","name":"RIBOMIC INC - Japan IR","isPartOf":{"@id":"https:\/\/japanir.jp\/en\/#website"},"datePublished":"2026-06-04T14:03:19+00:00","dateModified":"2026-08-23T04:29:35+00:00","breadcrumb":{"@id":"https:\/\/japanir.jp\/en\/company\/company-4591\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/japanir.jp\/en\/company\/company-4591\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/japanir.jp\/en\/company\/company-4591\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/japanir.jp\/en\/"},{"@type":"ListItem","position":2,"name":"RIBOMIC INC"}]},{"@type":"WebSite","@id":"https:\/\/japanir.jp\/en\/#website","url":"https:\/\/japanir.jp\/en\/","name":"Japan IR","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/japanir.jp\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/company\/60243","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/company"}],"about":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/types\/company"}],"wp:attachment":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/media?parent=60243"}],"wp:term":[{"taxonomy":"sector","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/sector?post=60243"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}